Scholarlink

Purpose of Review <p>Chronic hepatitis B is a global health concern which contributes to 820,000 deaths annually. Following World Health Organisation’s 2030 goal to eliminate viral hepatitis, recent initiatives aim to reduce (i) hepatitis-related deaths, and (ii) incidence of new chronic hepatitis infection.</p> Recent Findings <p>In 2022, Centers for Disease Control and Prevention (CDC) streamlined HBV vaccination coverage for all adults, shifting from previous policies of only recommending HBV vaccination in ‘high-risk’ groups. The move was targeted to reduce HBV-related mortality and morbidity, especially from acute HBV infections. New generation HBV vaccines such as (Heplisav-B<sup>®</sup> and PreHevbrio<sup>®</sup>) demonstrated non-inferiority in healthy adults and superior immunogenicity in traditional vaccine-poor responders when compared to traditional recombinant HBV vaccines, with equivalent safety profiles.</p> Summary <p> The new CDC policy changes together with utilisation of newer HBV vaccines promise to reduce acute and chronic HBV and its sequelae if implemented well.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Implementation of New Guidelines and Vaccines for the Prevention of Acute and Chronic HBV Infection

  • 期刊论文

  • 发表日期：

    2025年12月13日

查看全文
  • Hao Xing Lai,
  • Yong Chuan Tan,
  • Seng Gee Lim

摘要

Purpose of Review

Chronic hepatitis B is a global health concern which contributes to 820,000 deaths annually. Following World Health Organisation’s 2030 goal to eliminate viral hepatitis, recent initiatives aim to reduce (i) hepatitis-related deaths, and (ii) incidence of new chronic hepatitis infection.

Recent Findings

In 2022, Centers for Disease Control and Prevention (CDC) streamlined HBV vaccination coverage for all adults, shifting from previous policies of only recommending HBV vaccination in ‘high-risk’ groups. The move was targeted to reduce HBV-related mortality and morbidity, especially from acute HBV infections. New generation HBV vaccines such as (Heplisav-B® and PreHevbrio®) demonstrated non-inferiority in healthy adults and superior immunogenicity in traditional vaccine-poor responders when compared to traditional recombinant HBV vaccines, with equivalent safety profiles.

Summary

The new CDC policy changes together with utilisation of newer HBV vaccines promise to reduce acute and chronic HBV and its sequelae if implemented well.